Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cantex Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10836
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cantex Pharmaceuticals Inc (Cantex Pharmaceuticals), formerly ParinGenix Inc is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combination of disulfiram and copper that is in Phase II clinical trial for the treatment of recurrent glioblastoma; and completed Phase 1 trial in metastatic prostate cancer and breast cancer. Cantex Pharmaceuticals also develops CX-01 a polysaccharide used for the treatment of acute myeloid leukemia (AML), traumatic brain injury and other blood disorders. The company offers its products across the US. Cantex Pharmaceuticals is headquartered in Weston, Florida, the US.

Cantex Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cantex Pharma Raises Additional USD0.3 Million in Financing Round 10
Cantex Pharma Raises Additional USD1.6 Million in Financing Round 11
Cantex Pharma Raises USD0.7 Million in Financing Round 12
Paringenix Raises US$0.7 Million In Venture Financing 13
Acquisition 14
Shenzhen Hepalink Pharma to Invest USD30 Million in Cantex Pharma 14
Cantex Pharmaceuticals Inc – Key Competitors 16
Cantex Pharmaceuticals Inc – Key Employees 17
Cantex Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Clinical Trials 19
Oct 12, 2017: Lenox Hill Hospital participates in clinical research study to test investigational treatment for recurrent brain cancer 19
May 01, 2017: Cantex Pharmaceuticals Announces Initiation of Phase 2 Clinical Development for CX-02 in Recurrent Glioblastoma 20
Apr 04, 2017: Cantex Pharmaceuticals Announces Poster Presentation at AACR Annual Meeting 2017 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cantex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cantex Pharma Raises Additional USD0.3 Million in Financing Round 10
Cantex Pharma Raises Additional USD1.6 Million in Financing Round 11
Cantex Pharma Raises USD0.7 Million in Financing Round 12
Paringenix Raises US$0.7 Million In Venture Financing 13
Shenzhen Hepalink Pharma to Invest USD30 Million in Cantex Pharma 14
Cantex Pharmaceuticals Inc, Key Competitors 16
Cantex Pharmaceuticals Inc, Key Employees 17

List of Figures
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cantex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Methode Electronics Inc (MEI):企業の財務・戦略的SWOT分析
    Summary Methode Electronics Inc (Methode) is technology company. The company offers products such as automotive and transportation, high voltage switchgear, high-speed copper transceivers and modules, bus bars, custom user interface, dabir surfaces, discrete and analog switching, emi receptacles, fo …
  • Baidu, Inc.:企業のM&A・事業提携・投資動向
    Baidu, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Baidu, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • MCC EuroChem:企業の戦略的SWOT分析
    MCC EuroChem - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Telkom SA SOC Limited:企業の戦略・SWOT・財務情報
    Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Specsavers Optical Group Ltd:企業の戦略・SWOT・財務分析
    Specsavers Optical Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Specsavers Optical Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Meiji Holdings Co, Ltd.:企業の戦略・SWOT・財務分析
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Faron Pharmaceuticals Oy (FARN):企業の財務・戦略的SWOT分析
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that develops treatments for unmet medical needs. The company is developing pipeline products with a focus on vascular damage, acute organ traumas and cancer immunotherapy. It offers Clevegen, a humanized Clever-1 …
  • Mizuno Corporation (8022):企業の財務・戦略的SWOT分析
    Mizuno Corporation (8022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Endava Limited
    Endava Limited - Strategy, SWOT and Corporate Finance Report Summary Endava Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ProMetic Life Sciences Inc (PLI):製薬・医療:M&Aディール及び事業提携情報
    Summary ProMetic Life Sciences Inc (ProMetic) is a biopharmaceutical company that focuses on bioseparations, plasma-derived therapeutics and small-molecule drug development. The company develop products for the treatment for fibrosis, anemia, autoimmune diseases, inflammation and nephropathies. The …
  • Skinvisible Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Skinvisible Pharmaceuticals Inc (Skinvisible Pharmaceuticals), a subsidiary of Skinvisible Inc, is a pharmaceutical company that develops and manufactures prescription and over the counter dermatology, medical, cosmetic, consumer goods, and skincare products. The company provides products su …
  • Grupo Farma:企業の戦略的SWOT分析
    Grupo Farma - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Immunogen, Inc.:企業の戦略・SWOT・財務分析
    Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Principal Financial Group Inc:企業の戦略・SWOT・財務情報
    Principal Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Principal Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • ReWalk Robotics Ltd (RWLK):医療機器:M&Aディール及び事業提携情報
    Summary ReWalk Robotics Ltd (ReWalk) is a medical device company that designs, develops and commercializes exoskeletons. The company provides walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include ReWalk personal system and ReWalk rehabili …
  • JSC Inter RAO:企業のM&A・事業提携・投資動向
    JSC Inter RAO - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JSC Inter RAO Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Aquinox Pharmaceuticals Inc (AQXP)-製薬・医療分野:企業M&A・提携分析
    Summary Aquinox Pharmaceuticals Inc (Aquinox) is a clinical-stage pharmaceutical company which develops targeted therapeutics in the areas of inflammation and immuno-oncology. The company's lead product candidate AQX-1125, is a SHIP1 activator which is a natural modulator of the PI3K pathway to redu …
  • Bank of Kaohsiung, Ltd.:企業の戦略・SWOT・財務情報
    Bank of Kaohsiung, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Kaohsiung, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bel Fuse Inc. (BELFA):企業の財務・戦略的SWOT分析
    Bel Fuse Inc. (BELFA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Martin Midstream Partners LP (MMLP):企業の財務・戦略的SWOT分析
    Martin Midstream Partners LP (MMLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆